The potential for FGF-2 as a neurorestorative adjunct in stroke was first demonstrated in studies in which central administration of FGF-2 within 24 hr of MCAO induced improved motor recovery and the upregulation of growth-associated protein 43, a marker of axonal growth [27], [28]. The gene discussed is GAP43; the disease is stroke disorder.